Attendance at European Melioidosis Congress

RNS Number : 0232L
Poolbeg Pharma PLC
11 May 2022

Poolbeg Pharma plc


European Melioidosis Congress


Poolbeg to engage with key international stakeholders at congress as it develops

an intramuscular Melioidosis vaccine candidate


11 May 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 - 18 May 2022 in Graz, Austria, as it develops a Melioidosis vaccine candidate.


Poolbeg currently holds an option from University College Dublin to licence a late pre-clinical stage Melioidosis vaccine (POLB 003). There is currently no available vaccine on the market for Melioidosis, an infectious disease which is widespread in tropical and subtropical regions such as Northern Australia and Southeast Asia, with rising incidence around the world due to climate change. Caused by the bacteria Burkholderia pseudomallei, Melioidosis is intrinsically resistant to antibiotics and has global mortality rates up to 70%, depending on geography and bacterial load.


Learn more about POLB 003 here .


Jeremy Skillington, PhD, CEO of Poolbeg Pharma said : "Melioidosis presents a growing threat to health as a result of climate change, and is currently an infectious disease with no approved vaccine and a high mortality rate. At Poolbeg we are focused on targeting the significant global medical need to treat and prevent infectious diseases such as Melioidosis and we look forward to engaging with key scientific opinion leaders involved in the global effort to tackle and eliminate Melioidosis at the upcoming European Melioidosis Congress".


- Ends -



Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O'Connell, CFO


+44 (0) 207 183 1499

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, James Thompson, Charlie Beeson
Richard Chambers, Sunila de Silva (ECM)


+44 (0) 207 220 0500

Arden Partners PLC (Joint Broker)

John Llewellyn-Lloyd, Louisa Waddell


+44 (0) 207 614 5900

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist


+353 (0) 1 679 6363

Instinctif Partners

Melanie Toyne Sewell, Rozi Morris, Tim Field


+44 (0) 207 457 2020


About Poolbeg Pharma


Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to license or acquire.


The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.


With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001); a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) drug discovery programmes to accelerate the power of its human challenge model data and biobank.


For more information, please go to or follow us @PoolbegPharma

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings